M. D. Anderson Cancer Center SPORE in Multiple Myeloma

M.D. 安德森癌症中心 SPORE 治疗多发性骨髓瘤

• 批准号: 7939036
• 负责人: ROBERT ZYGMUNT ORLOWSKI
• 金额: $ 230万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-22 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7939036
• 关键词: M.; D.; Anderson; Cancer; Center

Multiple myeloma is a clonal plasma cell malignancy which, despite recent treatment advances, remains incurable in the vast majority of the over 59,000 patients in the United States afflicted with this disease. Therefore, The University of Texas M. D. Anderson Cancer Center, in collaboration with The University of Pennsylvania and the Virginia Commonwealth University, is proposing this Specialized Program of Research Excellence (SPORE) in Multiple Myeloma. The primary goal of this program will be to translate promising new strategies from the bench to the bedside to reduce the morbidity and mortality, and improve the quality of life of multiple myeloma patients. To do so, a multidisciplinary, collaborative group of experienced investigators will be pursuing four highly innovative Projects: Project 1 - Combination Activated T-Cell and Vaccine Therapy in Myeloma (Kwak/Giralt/June/Stadtmauer) Project 2 - Anti-(32-microglobulin Antibodies as Therapeutic Agents for Multiple Myeloma (Yi/Wang) Project 3-Targeting the HDM-2 E3 Ligase in Multiple Myeloma (Orlowski/Weber) Project 4 - Targeting Multiple Myeloma by Combining CDK Inhibitors and Bcl-2 Antagonists (Grant/Wang/Dai/Dent) To provide the specialized expertise needed to maximize the success of the Projects, they will be supported by five Core Facilities: Core A - Administrative Core Facility (Orlowski/Kwak) Core B - Myeloma Tissue Core Facility (Kornblau/Wang/Davis/Lin) Core C - Animal Models Core Facility (Yi/Yang) Core D - Clinical Trials Core Facility (Weber/Stadtmauer/McLaughlin) Core E - Biostatistics and Bioinformatics Core Facility (Berry/Baladandayuthapani/Almeida/ Ramakrishnan) Also, the SPORE will attract new investigators with additional novel ideas, and train the next generation of myeloma researchers, through the following Programs: Developmental Research Program (OrlowskiA'i) Career Development Program (Kwak/Aggarwal/Stadtmauer) This SPORE will therefore serve as a nexus for its Investigators and the myeloma research community to foster the kind of multidisciplinary efforts that are necessary to bring us closer to a cure for this disease.

多发性骨髓瘤是一种克隆性浆细胞恶性肿瘤，尽管最近治疗取得了进展，但在美国超过 59,000 名患有这种疾病的患者中，绝大多数患者仍然无法治愈。因此，德克萨斯大学 M.D. 安德森癌症中心与宾夕法尼亚大学和弗吉尼亚联邦大学合作，提出了这项多发性骨髓瘤专业卓越研究计划 (SPORE)。该计划的主要目标是将有前途的新策略从实验室转化为临床，以降低发病率和死亡率，并提高多发性骨髓瘤患者的生活质量。为此，由经验丰富的研究人员组成的多学科协作小组将开展四个高度创新的项目： 项目 1 - 骨髓瘤的激活 T 细胞和疫苗联合疗法 (Kwak/Giralt/June/Stadtmauer) 项目 2 - 抗（32-微球蛋白抗体）作为多发性骨髓瘤的治疗剂（Yi/Wang） 项目 3 - 靶向多发性骨髓瘤中的 HDM-2 E3 连接酶（Orlowski/Weber） 项目 4 - 通过结合 CDK 抑制剂和 Bcl-2 拮抗剂治疗多发性骨髓瘤 (Grant/Wang/Dai/Dent) 为了提供最大限度地提高项目成功所需的专业知识，他们将得到五个核心设施的支持： 核心 A - 行政核心设施（Orlowski/Kwak） 核心 B - 骨髓瘤组织核心设施（Kornblau/Wang/Davis/Lin） 核心 C - 动物模型核心设施（乙/阳） 核心 D - 临床试验核心设施（Weber/Stadtmauer/McLaughlin） 核心 E - 生物统计学和生物信息学核心设施（Berry/Baladandayuthapani/Almeida/Ramakrishnan） 此外，SPORE 将通过以下计划吸引具有更多新颖想法的新研究人员，并培训下一代骨髓瘤研究人员： 发展研究计划（OrlowskiA'i） 职业发展计划（Kwak/Aggarwal/Stadtmauer） 因此，该 SPORE 将成为其研究人员和骨髓瘤研究界的纽带，以促进必要的多学科努力，使我们更接近治愈这种疾病。